China's Great Wall interested in acquiring Fiat Chrysler: Great Wall official
Rosneft's strategic India deal in the bag
Stenson takes 54-hole lead at Wyndham C'ship
Total Buys Maersk Oil for $4.95 Billion
Confirmed: electric VW Microbus minivan due 2022, based on ID Buzz
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) & Synchrony Financial (NYSE:SYF) Watch List
20 April 2017, 05:40 | Kelvin Horton
The share price is now down -34.32% for the past three months. Finally, Guggenheim reaffirmed an "outperform" rating and issued a $10.00 price objective on shares of Synergy Pharmaceuticals in a research note on Thursday, March 2nd. Shares are trading 1.35% above their 50-day moving average, and 15.29% below their 200-day moving average.
Price Target is basically a projection of future price of a company's stock by the expert analysis of investment analysts or investment firms. Analyst's mean target price for PM is $114.14 while analysts mean recommendation is 2.50. These analysts and investment firms use various valuation methods to decide a price target for a stock.
Synergy Pharmaceuticals, Inc. (SGYP) has a market capitalization of 930.39 Million which suggests the company is a huge company further suggesting that the shares of Synergy Pharmaceuticals, Inc. The company has a consensus rating of Buy and an average price target of $11.63.
WARNING: "Synergy Pharmaceuticals Inc (SGYP) Shares Bought by Tudor Investment Corp Et Al" was first posted by BBNS and is the sole property of of BBNS.
Shares outstanding are recorded as 223.12 M and total shares floated are 215.24 M. Current ratio which is the relationship between current assets and current liabilities, indicating the liquidity of a business is calculated as 1.20. Analysts have a mean recommendation of 2.50 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range).
Synergy Pharmaceuticals (NASDAQ:SGYP) opened at 4.55 on Tuesday. This is built on a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.
Tudor Investment Corp Et Al increased its position in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) by 1.3% during the fourth quarter, according to its most recent disclosure with the SEC. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.20) by $0.11. The analysts offering Earnings Estimates for the company were believing that Synergy Pharmaceuticals, Inc. The difference between Actual EPS and Estimated EPS was -0.11 Percent. Institutional investors and hedge funds own 55.36% of the company's stock. (SGYP) now has a value of $4.17 while the company's 52 week low is at $2.62, the shares dropped to the 52 week low on 05/12/16. The stock appeared -38.18% below its 52-week highs and is up 3.76% for the last five trades. The stock traded at a volume of 5.19 million shares. The Moving Average SMA50 is -21.5% while SMA200 is -20.89%. Equities research analysts predict that Synergy Pharmaceuticals Inc will post ($0.72) EPS for the current fiscal year. The Return on Investment (ROI) is at 0% while it's Return on Equity (ROE) value stands at -876.7%.
Johnson & Johnson (NYSE:JNJ) have shown a high EPS growth of 11.20% in the last 5 years and has earnings growth of 20.10% yoy. This is a near-term estimation for the next 12-18 months. The last session's volume of 5.20 million shares was lower than its average volume of 6.70 million shares. Aperio Group LLC now owns 22,346 shares of the biopharmaceutical company's stock valued at $123,000 after buying an additional 7,249 shares in the last quarter. The stock now has Weekly Volatility of 4.47% and Monthly Volatility of 5.24%. SGYP has P/E (Price to Earnings ttm) value of 0, Forward P/E of 0, P/C (Price to cash per share) of 11.1 and Price to Free Cash Flow (P/FCF) value of 0.
Won't call police after overbooking, United CEO vows
Early on, United CEO Oscar Munoz added to the furor when he apologized for the incident but accused Dao of being belligerent. As for the passenger, Munoz said that he would like the opportunity to speak with him and apologize.
Browns have zeroed in on choice with No. 1 draft pick
Garrett can be a franchise-changing selection, even current Browns players realize (and are excited) about that possibility. Reports immediately emerged that the Browns would try to trade Osweiler again - and if all else failed they'd cut him.
Nigeria charges 53 over gay wedding
According to their defense lawyer, the suspects were detained for more than 24 hours, in violation of Nigerian law. Homosexual acts are illegal in the country and can attract a sentence of up to 14 years in jail.